The Cancer Immunotherapy program develops a low cost, personalized, simple, potentially safe and effective immunotherapy, called ConvitVax, targeted to underprivileged patients with breast cancer. This therapy combines the patient’s tumor cells with bacillus Calmette Guérin (BCG) and low concentrations of formalin. The vaccine combines the patient’s whole tumor cells, providing a broader load of antigenic epitopes; bacillus Calmette Guérin (BCG) as an adjuvant and low concentrations of formalin to attenuate the BCG and better present the antigens. This therapy is based on past successful experiences with therapeutic vaccines for leprosy and cutaneous leishmaniasis.
Studies in animals and a human pilot experience show that the combination of these components stimulate the immune system, achieving an effective and specific response against the body’s tumor cells with minimal to no side-effects and a possible establishment of immune memory, which may reduce the possibility of disease recurrence.
JCWO seeks to build international partnerships and raise funds to carry out clinical studies with ConvitVax and continue further research on combination therapies.
Our goal is to make this immunotherapy accessible to underprivileged woman who lack access to expensive treatments
Our immunotherapy timeline
Begins experimental research with the Mycobacterium leprae. Inoculates the bacteria in experimental animals.